Advanced Card Technologies LLC v. Versatile Card Technology, Inc.

410 F. Supp. 2d 158, 2006 U.S. Dist. LEXIS 1716, 2006 WL 162746
CourtDistrict Court, S.D. New York
DecidedJanuary 17, 2006
Docket04 CIV. 6888(CM)
StatusPublished
Cited by5 cases

This text of 410 F. Supp. 2d 158 (Advanced Card Technologies LLC v. Versatile Card Technology, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Advanced Card Technologies LLC v. Versatile Card Technology, Inc., 410 F. Supp. 2d 158, 2006 U.S. Dist. LEXIS 1716, 2006 WL 162746 (S.D.N.Y. 2006).

Opinion

MARKMAN OPINION

McMAHON, District Judge.

The Court, for its construction of the claims in suit:

Why a Markman Hearing in this Breach of Contract Case?

The action at bar is a breach of contract suit brought by a patentee against its licensee, for failure to remit royalties allegedly due. The licensee defends on the ground that the products on which it has refused to pay royalties are not covered by the patent and so are not subject to the license. Because defendant so contends, it is necessary to construe two patent claims, or the trier of fact will be unable to determine whether the products on which no royalties have been paid are covered by the license. Both parties have submitted extensive briefing on the construction of the two disputed claims that are in suit: Claim 8 of the so-called ’158 patent, and Claim 1 of the so-called ’584 patent.

Why Construe Claims That We Know Are Invalid

The parties advise me that both of these claims (and all other claims in these two patents that allegedly read on defendant’s products) were recently cancelled by the Patent Examiner, and new claims have apparently issued. One might well ask why a court should be forced to construe patent claims that it knows to be invalid. I myself have spent no little amount of time pondering that question.

The answer lies in the unusual facts of this case — facts that bring the matter within the narrow parameters of the largely-defunct doctrine of patent licensee es-toppel.

Defendant originally interposed an affirmative defense and a counterclaim in which it alleged lack of validity of the claims in suit. However, defendant admittedly had continued to (and as far as I am advised, still continues to) pay royalties on some products that it manufactures under the license, and has not contended that the license is no longer valid.

In an opinion dated October 19, 2005, (hereinafter “ACT /”), I dismissed the Third Affirmative Defense (lack of validity of the patent) under the doctrine of licensee estoppel. Because the parties made nothing of the licensee estoppel issue, I gave it short shrift in ACT I. I was a bit too cursory. I did not mean in ACT I to suggest that the doctrine of licensee estop- *161 pel had not been dealt a severe blow by the United States Supreme Court’s opinion in Lear v. Adkins, 395 U.S. 653, 89 S.Ct. 1902, 23 L.Ed.2d 610 (1969). However, as my esteemed colleague, Judge Kaplan, noted several years ago, “the doctrine of licensee estoppel is not entirely dead.” Revson v. Claire’s Stores, Inc., 120 F.Supp.2d 322, 326 (S.D.N.Y.2000). It is because licensee estoppel is not dead in this case that the court is forced to construe these two defunct patent claims. That being so, the reasons why licensee estoppel applies here should be stated more fulsomely than they were in ACT I.

VCT is estopped to challenge the validity of the patents in suit because it has neither ceased payment of royalties nor notified plaintiff that the reason for cessation was the claimed invalidity of the patents. See Studiengesellschaft Kohle, M.B.H. v. Shell Oil Co., 112 F.3d 1561 (Fed.Cir.), cert denied, 522 U.S. 996, 118 S.Ct. 560, 139 L.Ed.2d 401 (1997); see also Medimmune, Inc. v. Genentech, Inc., 427 F.3d 958, 965 (Fed.Cir.2005). It is undisputed that VCT has paid and continues to pay royalties to ACT for all products that VCT believes are covered by Claims 8 of the 158 patent and 1 of the ’584 patent. It is also undisputed that VCT has refused to pay royalties to ACT for other products it manufactures — the royalties that are the subject of this action — only because it believes that those claims do not read on certain of its products, and not because the claims are invalid. No party has suggested, and I have no reason to believe, that VCT has ever notified ACT that the reason it is not paying the royalties that are the subject of this action is that the claims in suit are invalid. Thus, the Kohle exception to Lear applies.

Of course, Kohle is a Federal Circuit opinion, and since this case does not “arise under” the patent laws, it is not going to be heard on appeal by the Federal Circuit. It will be heard by the Second Circuit (if it goes to any Court of Appeals at all). I have not found any Second Circuit case adopting the Kohle exception, although as the Kohle court itself notes, several other Circuits, including the Third, Sixth, Ninth and Tenth, follow the same rule. Kohle, supra, 112 F.3d at 1568. However, the Federal Circuit’s primacy in matters pertaining to patent law is such that, in the absence of direct Second Circuit precedent on the point, it is appropriate to rely on Kohle and to apply it to this case.

Therefore, just as the defendant in Rev-son was barred from asserting an invalidity defense to royalty payments that accrued in respect of sales occurring prior to the filing of the in that action, so here VCT may not assert its Third Affirmative Defense to royalty payments that were not made in respect of sales accruing prior to the filing of this action. That is why I must go through with this otherwise pointless exercise.

In view of the Examiner’s action, I remain puzzled by defendant’s stance in respect of its license. Were the defendant now to cease paying royalties on the products that it admits are covered by the invalidated claims, and notify ACT and this Court that it was doing so on the ground of invalidity, then it might well be entitled to amend its answer and reassert the stricken Third Affirmative Defense in respect of any sales made between the date of the disavowal and the date of the judgment (if any) in this action. Indeed, if it were accompanied by a complete cessation of royalty payments, VCT’s assertion of the now-dismissed First Counterclaim (invalidity) could provide the requisite notice to plaintiff that defendant contested the validity of the licensed patents, thus satisfying Kohle and permitting the reassertion of the Third Affirmative Defense as to any sales occurring between the date of cessa *162 tion and the date of judgment. 1 However, I have not been apprised of any cessation in the royalty payments that VCT had hitherto been making. Nor has VCT told anyone that it is not paying royalties because the claims that read on its products have been invalidated. Indeed, at our last pre-trial conference, defendant’s counsel expressed some alarm at the court’s suggestion that the license might in fact be invalid now that the patents contain different claims than the now-invalidated ones that existed when the parties originally contracted. Defendant’s reasons for taking the position it presently adopts are, frankly, not the court’s concern. I take the case as it is given to me. As given to me, the Third Affirmative Defense was properly stricken.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

EPITOPIX, LLC v. ZOETIS INC.
D. New Jersey, 2025
Schindler Elevator Corp. v. Otis Elevator Co.
561 F. Supp. 2d 352 (S.D. New York, 2008)
MedImmune, Inc. v. Genentech, Inc.
535 F. Supp. 2d 1000 (C.D. California, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
410 F. Supp. 2d 158, 2006 U.S. Dist. LEXIS 1716, 2006 WL 162746, Counsel Stack Legal Research, https://law.counselstack.com/opinion/advanced-card-technologies-llc-v-versatile-card-technology-inc-nysd-2006.